| Literature DB >> 31105122 |
Takeshi Oba1, Shunsuke Kobayashi1, Yuko Nakamura1, Mototsugu Nagao1, Kandai Nozu2, Izumi Fukuda1, Kazumoto Iijima2, Hitoshi Sugihara1.
Abstract
A 21-year-old man presented with hyperthyroidism and hypokalemia and was treated for thyrotoxic hypokalemic periodic paralysis caused by Graves' disease. Thyroid function soon normalized but hypokalemia persisted. Laboratory data revealed hyperreninemic hyperaldosteronism and metabolic alkalosis consistent with Gitelman Syndrome. The patient was found to have a previously unreported compound heterozygous mutation of T180K and L858H in the SLC12A3 gene, and Gitelman Syndrome was diagnosed. He was started on eplerenone to control serum potassium level. Alternative diagnoses should be considered when electrolyte imbalances persist after disease resolution.Entities:
Keywords: Gitelman syndrome; SLC12A3 gene; eplerenone; hypokalemia; thyrotoxic hypokalemic periodic paralysis
Mesh:
Substances:
Year: 2019 PMID: 31105122 DOI: 10.1272/jnms.JNMS.2019_86-505
Source DB: PubMed Journal: J Nippon Med Sch ISSN: 1345-4676 Impact factor: 0.920